Home
Patient Center
Clinical Trial
About Us
Chairman’s Message
Our Company
Leadership
Research&Development
Areas of Focus
Pipeline
Newsroom
Company News
Guidelines&Recomandations
Publications
Contact Us
Contacts
中文
English
中文
English
Home
Patient Center
Clinical Trial
About Us
Chairman’s Message
Our Company
Leadership
Research&Development
Areas of Focus
Pipeline
Newsroom
Company News
Guidelines&Recomandations
Publications
Contact Us
Contacts
Learn More
Gensciences receives FDA Orphan Drug Designation for FRSW117, once-a-week ultra-long-acting recombinant coagulation FVIII Drugs
2024-09-26
Learn More
Gensciences will Expose Its Data at ISTH 2024
2024-06-17
Learn More
Gensciences Inc. Initiated Phase III Clinical Trial for Its Ultra-Long-Acting Recombinant Coagulation Factor VIII with Once-Weekly Dosing Regimen!
2023-12-25
Learn More
More News
Research&Development
Learn More
Areas of Focus
Pipeline